Precision BioSciences Says Baxalta's IO Focus Made It Preferred Partner
This article was originally published in Scrip
Executive Summary
Genome-editing specialist Precision BioSciences says Baxalta Inc.'s increasing commitment to, and expertise in, immuno-oncology made it the obvious choice for the Duke University spinout to partner with on developing a broad series of allogeneic chimeric antigen receptor (CAR) T cell therapies directed against multiple cancers.
You may also be interested in...
CRISPR Therapeutics, Vertex Initiate First Industry-Sponsored Trial – What’s Next?
CRISPR Therapeutics and Vertex initiated the first human study of CRISPR gene-editing technology with an industry sponsor, following an investigator-sponsored study initiated in China two years ago. These are not the first gene-editing trials, but they're important milestones for the CRISPR field.
Meek To Drive M&A At Ipsen, Building On Two Major Launches
France’s Ipsen is preparing to launch Cabometyx in Europe this autumn and telotristat next year, and the business development expertise of its new CEO will be useful in replenishing its product portfolio.
Ipsen Appoints Baxalta's Oncology Chief Meek CEO
Ipsen has appointed Baxalta's head of oncology David Meek as its new CEO, having formerly instigated a search in February. Baxalta's $32bn acquisition by Shire completed at the start of June.